1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. ACT Genomics Acquires MC Diagnostics

M&A Deal Summary

ACT Genomics Acquires MC Diagnostics

On August 10, 2021, ACT Genomics acquired life science company MC Diagnostics

Acquisition Highlights
  • This is ACT Genomics’ 1st transaction in the Life Science sector.
  • This is ACT Genomics’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-08-10
Target MC Diagnostics
Sector Life Science
Buyer(s) ACT Genomics
Deal Type Add-on Acquisition

Target

MC Diagnostics

Denbighshire, United Kingdom
MC Diagnostics specializes in the design and development of molecular diagnostics across the fields of immunogenetics, immunology, blood banking, and microbiology. MC Diagnostics was founded in 2006 and is based in Denbighshire, United Kingdom.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ACT Genomics

Taipei, Taiwan
Category Company
Founded 2014
Sector Life Science
DESCRIPTION

ACT Genomics provides optimal cancer treatment plans, cancer relapse, and drug resistance monitoring as well as cancer risk assessment and immunotherapy evaluation through DNA sequencing-based technology. ACT Genomics achieves precise cancer genetic variants detection with minimum tumor samples and delivers to every cancer patient personalized genomic, information-based treatment plans through a cutting-edge NGS platform, medical reports, and integrated services. ACT Genomics was founded in 2014 and is based in Taipei, Taiwan.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal